NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$76.27

+1.86 (+2.50%)

(As of 08/19/2022 12:00 AM ET)

Add

Compare

Today's Range: $75.86
▼
$80.00
50-Day Range: $50.46
▼
$82.40
52-Week Range: $38.86
▼
$102.99

Volume: 141,673 shs
Average Volume: 195,455 shs
Market Capitalization: $1.96 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $105.20

Krystal Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 37.9% Upside
$105.20 Price Target
Short Interest: Bearish
6.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 0.19
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.36) to ($4.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

431st out of 1,116 stocks

Biological Products, Except Diagnostic Industry

61st out of 178 stocks

3.5

Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $105.20, Krystal Biotech has a forecasted upside of 37.9% from its current price of $76.27.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.97% of the float of Krystal Biotech has been sold short.
Short Interest Ratio / Days to Cover
Krystal Biotech has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Krystal Biotech has recently decreased by 1.44%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Krystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Krystal Biotech is -0.87.

1.8

News and Social Media Coverage

News Sentiment
Krystal Biotech has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.80% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
76.57% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to grow in the coming year, from ($5.36) to ($4.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -16.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -16.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech Trading Up 3.9 %

Shares of KRYS traded up $2.91 during mid-day trading on Friday, reaching $77.32. The company had a trading volume of 1,875 shares, compared to its average volume of 157,684. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -16.38 and a beta of 0.88. The firm has a fifty day simple moving average of $69.47 and a 200-day simple moving average of $65.35. Krystal Biotech has a fifty-two week low of $38.86 and a fifty-two week high of $102.99.

Krystal Biotech (NASDAQ:KRYS - Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.11). As a group, equities analysts predict that Krystal Biotech will post -5.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on KRYS shares. The Goldman Sachs Group decreased their price target on Krystal Biotech from $91.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th. Chardan Capital lowered their target price on shares of Krystal Biotech from $137.00 to $130.00 and set a "buy" rating for the company in a research note on Tuesday, August 9th.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

August 19, 2022 | finance.yahoo.com

FDA reviewing Krystal Biotech's biologics application

August 18, 2022 | markets.businessinsider.com

FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review

August 18, 2022 | finance.yahoo.com

FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

August 18, 2022 | seekingalpha.com

Krystal Biotech: Solid Performance, Let's Keep Holding

August 13, 2022 | americanbankingnews.com

Q3 2022 EPS Estimates for Krystal Biotech, Inc. Decreased by William Blair (NASDAQ:KRYS)

August 11, 2022 | americanbankingnews.com

Chardan Capital Lowers Krystal Biotech (NASDAQ:KRYS) Price Target to $130.00

August 9, 2022 | americanbankingnews.com

IN8bio (NASDAQ:INAB) vs. Krystal Biotech (NASDAQ:KRYS) Financial Contrast

August 9, 2022 | americanbankingnews.com

Krystal Biotech (NASDAQ:KRYS) and IN8bio (NASDAQ:INAB) Head to Head Survey

August 8, 2022 | finance.yahoo.com

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

August 1, 2022 | finance.yahoo.com

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

August 1, 2022 | bizjournals.com

FDA approves Krystal Biotech clinical trial

August 1, 2022 | finance.yahoo.com

Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

July 12, 2022 | thestreet.com

Biotech Can't Conquer the Lungs. Will These Stocks Succeed?

July 6, 2022 | finance.yahoo.com

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

June 22, 2022 | markets.businessinsider.com

Krystal Biotech Files To Seek Approval For Skin Disease Candidate

June 22, 2022 | finance.yahoo.com

Krystal Biotech applies for biologics license for gene therapy

June 22, 2022 | seekingalpha.com

Krystal Biotech files for FDA approval of topical gene therapy for rare skin disorder

June 22, 2022 | finance.yahoo.com

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

June 7, 2022 | finance.yahoo.com

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

May 25, 2022 | seekingalpha.com

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 23, 2022 | finance.yahoo.com

Krystal Biotech Stock Flashes Renewed Technical Strength

May 19, 2022 | finance.yahoo.com

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

May 10, 2022 | bizjournals.com

Krystal Biotech says it's on schedule for filing for license with FDA

May 9, 2022 | finance.yahoo.com

Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates

May 9, 2022 | nasdaq.com

Oversold Conditions For Krystal Biotech (KRYS)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings: 8/08/2022
Today: 8/19/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRYS
CUSIP: N/A
CIK: 1711279
Web: www.krystalbio.com
Phone: (412) 586-5830
Fax: N/A
Employees: 119
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $105.20
High Stock Price Forecast: $130.00
Low Stock Price Forecast: $78.00
Forecasted Upside/Downside: +37.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -17.15%
Return on Assets: -15.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.45
Quick Ratio: 12.45

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $21.79 per share
Price / Book: 3.50

Miscellaneous

Outstanding Shares: 25,664,000
Free Float: 21,096,000
Market Cap: $1.96 billion
Optionable: Not Optionable
Beta: 0.88

Key Executives

Mr. Krish S. Krishnan M.B.A. (Age 57)
M.S., Founder, Chairman, Pres & CEO
Comp: $1.01M

Ms. Suma M. Krishnan (Age 57)
Founder, COO, Pres of R&D and Director
Comp: $708.56k

Ms. Kathryn A. Romano (Age 41)
Exec. VP & Chief Accounting Officer
Comp: $452.43k

Dr. Jing L. Marantz M.B.A. (Age 57)
M.D., Ph.D., Exec. VP & Chief Bus. Officer
Comp: $46.7k

Dr. Andreas C. Orth (Age 52)
Exec. VP & Chief Commercial Officer
Comp: $549.17k

Ms. Gloria Lin
Accounting Mang.

Ms. Meg Dodge
VP of Investor Relations & Corp. Communications

Mr. David Glynn
Gen. Counsel, Commercial & Compliance

Mr. John Karakkal
VP of North American Sales & Marketing

Ms. Katherine Tuminello
HR & Office Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.
What is Krystal Biotech's stock price forecast for 2022?: 4 equities research analysts have issued 1-year price objectives for Krystal Biotech's stock. Their KRYS share price forecasts range from $78.00 to $130.00. On average, they expect the company's stock price to reach $105.20 in the next year. This suggests a possible upside of 37.9% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.
How have KRYS shares performed in 2022?: Krystal Biotech's stock was trading at $69.95 at the beginning of the year. Since then, KRYS shares have increased by 9.0% and is now trading at $76.27.
View the best growth stocks for 2022 here.
When is Krystal Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our KRYS earnings forecast.
How were Krystal Biotech's earnings last quarter?: Krystal Biotech, Inc. (NASDAQ:KRYS) released its earnings results on Monday, August, 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by $0.11.
What other stocks do shareholders of Krystal Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?: (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.
What is Krystal Biotech's stock symbol?: Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
Who are Krystal Biotech's major shareholders?: Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (8.21%), Point72 Asset Management L.P. (6.13%), Frazier Life Sciences Management L.P. (4.27%), State Street Corp (4.04%), Pictet Asset Management SA (2.91%) and Credit Suisse AG (2.74%). Insiders that own company stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.
How do I buy shares of Krystal Biotech?: Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Krystal Biotech's stock price today?: One share of KRYS stock can currently be purchased for approximately $76.27.
How much money does Krystal Biotech make?: Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $1.96 billion. The company earns $-69,570,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis.
How many employees does Krystal Biotech have?: The company employs 119 workers across the globe.
How can I contact Krystal Biotech?: Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 8/20/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Krystal Biotech - KRYS Stock Forecast, Price & News

Krystal Biotech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month